

De Novo Truncating Mutations in *AHDC1* in Individuals with Syndromic Expressive Language Delay, Hypotonia, and Sleep Apnea

Fan Xia,¹ Matthew N. Bainbridge,² Tiong Yang Tan,^{3,4} Michael F. Wangler,^{1,5} Angela E. Scheuerle,⁶ Elaine H. Zackai,⁷ Margaret H. Harr,⁷ V. Reid Sutton,^{1,5} Roopa L. Nalam,^{2,8} Wenmiao Zhu,¹ Margot Nash,³ Monique M. Ryan,³ Joy Yapliito-Lee,³ Jill V. Hunter,⁵ Matthew A. Deardorff,⁷ Samantha J. Penney,¹ Arthur L. Beaudet,¹ Sharon E. Plon,^{1,5} Eric A. Boerwinkle,^{2,9} James R. Lupski,^{1,5} Christine M. Eng,¹ Donna M. Muzny,² Yaping Yang,¹ and Richard A. Gibbs^{1,2,*}

Clinical whole-exome sequencing (WES) for identification of mutations leading to Mendelian disease has been offered to the medical community since 2011. Clinically undiagnosed neurological disorders are the most frequent basis for test referral, and currently, approximately 25% of such cases are diagnosed at the molecular level. To date, there are approximately 4,000 “known” disease-associated loci, and many are associated with striking dysmorphic features, making genotype-phenotype correlations relatively straightforward. A significant fraction of cases, however, lack characteristic dysmorphism or clinical pathognomonic traits and are dependent upon molecular tests for definitive diagnoses. Further, many molecular diagnoses are guided by recent gene-disease association discoveries. Hence, there is a critical interplay between clinical testing and research leading to gene-disease association discovery. Here, we describe four probands, all of whom presented with hypotonia, intellectual disability, global developmental delay, and mildly dysmorphic facial features. Three of the four also had sleep apnea. Each was a simplex case without a remarkable family history. Using WES, we identified *AHDC1* de novo truncating mutations that most likely cause this genetic syndrome.

De novo pathogenic mutations are a major cause of sporadic human genetic disease.^{1,2} Whole-exome sequencing (WES)³ using next-generation-sequencing methods has proven to be a powerful tool for molecular diagnosis of mutations in genes known to underlie Mendelian disease,¹ as well as for the discovery of novel disease-associated loci.⁴ Despite the rapid development of these new molecular tools, the majority of individuals who are suspected to have a genetic disease remain undiagnosed. In part, this reflects the incomplete status of the catalog of characterized Mendelian-disease-associated genes; this catalog currently includes about 4,000 entries and represents less than one-quarter of the annotated genes (~21,000) in the human genome.

We applied WES to identify de novo genetic changes in a parent-offspring trio in which the proband exhibited developmental delay, hypotonia, mild dysmorphic features, sleep apnea, and other symptoms (Figure 1; Table 1; Table S1, available online). A truncating de novo mutant allele was found in AT-hook, DNA-binding motif, containing 1 (*AHDC1* [RefSeq accession number NM_001029882.2]). We subsequently identified an additional three independent simplex cases with similar phenotypes and de novo truncating events in the same gene. This pattern of de novo variation in *AHDC1* is highly unlikely to have occurred by chance and most likely represents the underlying cause of the symptoms in these individuals.

Subject 1 was an 18-month-old female (born to unrelated parents) who presented with hypotonia, delayed motor milestones, dysmorphic features, hepatomegaly, and laryngomalacia (Figure 2). Both the healthy parents and the proband were analyzed by WES.¹ Informed consent was obtained, and all procedures were followed in accordance with the ethical standards prescribed and approved by the Baylor College of Medicine Institutional Review Board. The DNA from each of the three samples was sequenced at an average depth of coverage of greater than 120-fold, and greater than 95% of the targeted bases were covered at 20-fold or higher. The results identified de novo events, including single-nucleotide variants (SNVs) or small indel mutations in the proband, in five genes: c.415G>A (p.Glu139Lys) in *CALY* (MIM 604647; RefSeq NM_015722.3), c.1429G>A (p.Gly477Arg) in *PTPRB* (MIM 176882; RefSeq NM_001109754.2), c.1076C>A (p.Ala359Glu) in *TBCK* (RefSeq NM_033115.4), c.1093dup (p.Met365Asnfs*4) in *CCDC66* (RefSeq NM_001141947.1), and c.2373_2374 delTG (p.Cys791Trpfs*57) in *AHDC1*; all sequence coordinates are based on human reference genome hg19 (UCSC Genome Browser). A comparison of the minor allele frequencies between these variants and similar mutations in the NHLBI Exome Sequencing Project Exome Variant Server (EVS) and a local variant database (see below) eliminated three missense mutations and one putative

¹Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; ²Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA; ³Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, VIC 3052, Australia; ⁴Department of Pediatrics, University of Melbourne, Parkville VIC 3052, Australia; ⁵Texas Children's Hospital, Houston, TX 77030, USA; ⁶Tesserae Genetics, Dallas, TX 75230, USA; ⁷The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA; ⁸Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA; ⁹Human Genetics Center, University of Texas Health Science Center, Houston, TX 77030, USA

*Correspondence: agibbs@bcm.edu

<http://dx.doi.org/10.1016/j.ajhg.2014.04.006>. ©2014 by The American Society of Human Genetics. All rights reserved.




Figure 1. Pedigrees and Mutations of Four Affected Families

frameshift mutation as likely disease-causing candidates because of their occurrence in individuals without suspected developmental disorders. The remaining variant, the de novo deletion mutation in *AHDC1* (c.2373_2374delTG), results in a frameshift of the *AHDC1* open reading frame, beginning at codon 791, and by conceptual translation is predicted to cause a pre-

mature termination codon (p.Cys791Trpfs*57). Predicted truncating mutations in *AHDC1* are absent from the 1000 Genomes database (healthy individuals), the EVS (about 6,500 individuals), and a database of exome data from the Atherosclerosis Risk in Communities study (approximately 8,000 community-based individuals). The absence of truncating mutations in *AHDC1* in these databases suggests that such gene perturbations are not consistent with general good health, and therefore the observed *AHDC1* mutation was considered likely to be pathogenic.

We next screened 2,000 entries of clinical WES data at the Whole Genome Laboratory at Baylor College of Medicine to identify possible additional *AHDC1* mutations. Those data consist primarily of individuals who had a sample submitted by their physician for clinical WES, as previously described.¹ The clinical WES test focuses on exome sequencing of the proband, and complete parental WES data are not routinely generated. Among 2,000 previously tested individuals, of whom 1,700 had developmental delay and/or intellectual disabilities, three were found to harbor frameshift alleles in *AHDC1* (c.2898delC [p.Tyr967Thrfs*175] at chr1: 27,875,729, c.2373_2374delTG [p.Cys791Trpfs*57] at chr1: 27,876,253–27,876,254, and c.2547delC [p.Ser850Profs*82] at chr1: 27,876,080; [Figures 1 and 3](#)). The

Table 1. Major Clinical Features of Four Probands

	Subject			
	1	2	3	4
Gender	female	female	male	male
Age	18 months	4 years	8 years	11 years
Ethnicity	European descent	South Asian	European descent	European descent
Intellectual disability	NA	moderate	mild	moderate to severe
Speech delay	no words at 18 months of age	two words at 4 years of age	first words after 1 year of age, persistent speech therapy	no words, noncommunicating autism
Motor delay	no sitting at 18 months of age	sitting at 19 months of age, walking at 24 months of age	sitting at 9 months of age, walking at 18 months of age	sitting at 15 months of age, no independent ambulation
Hypotonia and failure to thrive	yes	yes	yes	yes
Dysmorphic facial features	low-set ears, esotropia, upslanting palpebral fissures, micrognathia, flat nasal bridge	protuberant ears, upslanting palpebral fissures, flat nasal bridge	protuberant low-set ears, small earlobes, hypertelorism, downslanting palpebral fissures, mild ptosis, micrognathia	upturned earlobes, hypertelorism, esotropia, flat nasal bridge
Anatomic upper-airway obstruction	laryngomalacia, obstructive sleep apnea	obstructive sleep apnea	laryngomalacia, obstructive sleep apnea	suspected tracheomalacia in infancy, history of snoring
Family history	negative, one healthy sibling	negative	negative, one healthy sibling	negative, two healthy siblings
Previous testing	MD, SMA, PWS, CMA, metabolic work-up	FX, CMA (18 Mb AOH on chromosome 5), metabolic work-up	CMA, FX, metabolic work-up	SMA, PWS, CMA, metabolic work-up

See [Table S1](#) for additional details of clinical presentations. Abbreviations are as follows: AOH, absence of heterozygosity; CMA, chromosome microarray; FX, fragile X chromosome; MD, myotonic dystrophy; NA, not available; PWS, Prader-Willi syndrome; and SMA, spinal muscular atrophy.




Figure 2. Facial Features of Proband

(A) Subject 1 (17 months old) with a round face, full cheeks, horizontal eyebrows, a depressed nasal bridge, anteverted nares, hypoplastic alae nasi, tented upper-lip vermillion, and microstomia.

(B) Subject 2 (4 years old) with thin eyebrows, a depressed nasal bridge, a bulbous nasal tip, and protuberant ears.

(C) Subject 3 (8 years old) with horizontal eyebrows, low-set ears, simple earlobes, and micrognathia.

(D) Subject 4 (21 months old) with a round face, full cheeks, horizontal eyebrows, a depressed nasal bridge, anteverted nares, tented upper-lip vermillion, and microstomia.

(E and F) Front (E) and side (F) views of subject 4 (9 years old) with a round face, full cheeks, horizontal eyebrows, an acute nasal angle, and fleshy pinna.

mutations in the three individuals were further demonstrated by PCR and Sanger DNA sequencing to be absent in maternal and paternal DNA and were therefore interpreted as de novo events. Interestingly, subjects 1 and 3 had the same de novo mutation (c.2373_2374delTG [p.Cys791Trpfs*57]). Except for the *AHDC1* mutations, we did not find other molecular events that could potentially explain the conditions in these probands. Therefore, the de novo mutations observed here in *AHDC1* are the most likely causes of the disease.

Clinical review of the four probands with *AHDC1* truncating mutations revealed that all had a history of congenital hypotonia and failure to thrive (Table 1; Table S1). The developmental histories were all remarkable for delayed speech, especially expressive language. All had mildly dysmorphic facial features that could be seen at a young age, and those of subject 4 persisted at an older age. Three probands also had a history of obstructive sleep apnea, potentially because of upper-airway structural abnormal-

ities. All probands had prior brain MRI demonstrating hypoplasia of the corpus callosum. Simplification of the gyral pattern and delayed myelination were also observed. A retrocerebellar cyst was present in two of the four subjects (Figure S1).

The independent occurrence of four de novo mutational events at this locus in individuals with similar phenotypes is highly unlikely⁵ (discussed in Bainbridge et al.⁶) and can be asserted as extremely strong evidence that these mutations in *AHDC1* cause this simplex disorder. To the best of our knowledge, the overall clinical presentations of these probands do not precisely match any previously known disease and, together with the statistical and molecular data, suggest a genetic syndrome defined by the mutations in *AHDC1*.

In subject 4, we also identified a de novo missense change, c.2006A>C (p.Asp669Ala), in *ANKRD11* (MIM 611192; RefSeq NM_013275.5). Haploinsufficiency of *ANKRD11* has been associated with KBG syndrome (MIM




Figure 3. AHDC1 Genomic Organization

(A) Chromosomal location of *AHDC1* and the genomic region surrounding it.

(B and C) Organization of *AHDC1* (B) and the AT-hook DNA-binding region, conserved regions, and location of the three different truncating alterations in the disorder (C). The histogram shows evolutionary conservation (see Figure S3 for details).

148050), characterized by macrodontia, variable facial dysmorphic features, mild skeletal anomalies, seizures in some individuals, and mild to moderate intellectual disability. However, the proband reported here did not have macrodontia, skeletal defects, or other features of KGB phenotypes and therefore did not meet the KGB diagnostic criteria proposed by Skjei et al.⁷ Additionally, the well-characterized pathogenic mutations in *ANKRD11* are truncating.⁸ Thus, the significance of *ANKRD11* missense variant c.2006A>C (p.Asp669Ala) is unclear.

AHDC1 is located on the short arm of chromosome 1 within the cytogenetic band 1p36.11, but it is more proximal than the regions identified from partial or complete monosomy of 1p36,⁹ other small interstitial deletions,^{10,11} and the nearby *ARID1A*, mutations in which cause autosomal-dominant Coffin-Siris syndrome¹² (MIM 135900). In the RefSeq and CCDS databases, the structural organization of *AHDC1* includes five untranslated exons upstream of a single 4,929 bp coding exon followed by a single downstream exon. This intronless coding structure is a common feature for newly evolved genes created by RNA-based retroposition.¹³ Indeed, orthologs of *AHDC1* can only be found in vertebrate animals. Gaining intron

structures during evolution is correlated with higher expression levels.¹⁴ The expression level and patterns of *AHDC1* are more similar to those of the multi-intron *ARID1A* than to those of the intronless *FOXG1* (MIM 164874), two other genes associated with severe developmental disorders in humans (Figure S2). Therefore, it can be postulated that the introns of the UTRs of *AHDC1* affect and/or enhance the expression levels in various human tissues. On the nucleotide level, the single coding exon of *AHDC1* is well conserved among vertebrates (Figure 3). The 3' untranslated exon also shows conservation levels similar to those of the coding region, suggesting a potential functional significance of this exon.

Human *AHDC1* encodes a protein of 1,603 amino acids. By aligning human *AHDC1* against the protein sequences of *AHDC1* orthologs in mouse, zebrafish, and western clawed frog, we found that the conserved amino acids are clustered into two regions (Figure 3C; Figure S3), suggesting two functional units. *AHDC1* has two AT-hook DNA-binding motifs located at codons 396–408 and 544–556, contained in conserved region 1. AT-hook domains are DNA-binding motifs that act to fasten proteins to AT-rich sequences in DNA.¹⁵ Although conserved, region 2

contains no known functional domains. In vitro protein-interaction assays have shown that AHDC1 interacts with a number of other nuclear proteins.^{16–21} Therefore, conserved regions 1 and 2 of AHDC1 might interact with the DNA elements or protein partners. Interestingly, all of the de novo mutations found in these four probands might truncate conserved region 2 but preserve region 1. Given that each mutation identified here occurs in a single coding exon, the modified mRNA might escape nonsense-mediated decay,²² suggesting that the autosomal-dominant mode of inheritance of these mutations is possibly due to the formation of dominant-negative proteins rather than haploinsufficiency.

Future research to better delineate the functional domains of AHDC1 is now enhanced by the phenotypic association with the truncating mutations reported here. Also, the phenotypes of the four probands are clearly similar in retrospect. However, speech delay and obstructive sleep apnea are sufficiently common conditions that it is unlikely that this syndrome would have been identified if the de novo mutations had not been uncovered first.

Supplemental Data

Supplemental Data include three figures and one table and can be found with this article online at <http://dx.doi.org/10.1016/j.ajhg.2014.04.006>.

Acknowledgments

We thank the families and clinical staff at all locations for participation in this study. This work was supported in part by NIH grants to R.A.G. (NHGRI 5 U54 HG003273), J.R.L. (NHGRI RO1NS058529 and U54HG006542), and S.E.P. (NHGRI 5 U01 HG006485). M.W. received funding from the National Institute of Neurological Disorders and Stroke (NS076547) and the Simons Foundation. T.Y.T. is partially supported by the National Health and Medical Research Council of Australia (fellowship 607431). Baylor College of Medicine performs genetic testing as a service for a fee. M.N.B. is a founder of Codified Genomics, and J.R.L. is a consultant for Athena Diagnostics, 23andMe, and Ion Torrent Systems Inc. and holds multiple US and European patents for DNA diagnostics.

Received: February 2, 2014

Accepted: April 8, 2014

Published: May 1, 2014

Web Resources

The URLs for data presented herein are as follows:

Atherosclerosis Risk in Communities Study, <http://www2.csc.unc.edu/aric/>

Baylor College of Medicine Whole Genome Laboratory, <https://www.bcm.edu/research/medical-genetics-labs/wholegenomelab>

CCDS, <http://www.ncbi.nlm.nih.gov/CCDS/CcidsBrowse.cgi>

ClinVar, <https://www.ncbi.nlm.nih.gov/clinvar/>

NHLBI Exome Sequencing Project (ESP) Exome Variant Server, <http://evs.gs.washington.edu/EVS/>

Online Mendelian Inheritance in Man (OMIM), <http://omim.org/>
RefSeq, <http://www.ncbi.nlm.nih.gov/refseq/>

Accession Numbers

The ClinVar accession numbers for the DNA variant data reported in this paper are SCV000148377, SCV000148378, and SCV000148379.

References

1. Yang, Y., Muzny, D.M., Reid, J.G., Bainbridge, M.N., Willis, A., Ward, P.A., Braxton, A., Beuten, J., Xia, F., Niu, Z., et al. (2013). Clinical whole-exome sequencing for the diagnosis of mendelian disorders. *N. Engl. J. Med.* 369, 1502–1511.
2. Veltman, J.A., and Brunner, H.G. (2012). De novo mutations in human genetic disease. *Nat. Rev. Genet.* 13, 565–575.
3. Bainbridge, M.N., Wang, M., Burgess, D.L., Kovar, C., Rodesch, M.J., D'Ascenzo, M., Kitzman, J., Wu, Y.Q., Newsham, I., Richmond, T.A., et al. (2010). Whole exome capture in solution with 3 Gbp of data. *Genome Biol.* 11, R62.
4. Gonzaga-Jauregui, C., Lupski, J.R., and Gibbs, R.A. (2012). Human genome sequencing in health and disease. *Annu. Rev. Med.* 63, 35–61.
5. Neale, B.M., Kou, Y., Liu, L., Ma'ayan, A., Samocha, K.E., Sabo, A., Lin, C.F., Stevens, C., Wang, L.S., Makarov, V., et al. (2012). Patterns and rates of exonic de novo mutations in autism spectrum disorders. *Nature* 485, 242–245.
6. Bainbridge, M.N., Hu, H., Muzny, D.M., Musante, L., Lupski, J.R., Graham, B.H., Chen, W., Gripp, K.W., Jenny, K., Wienker, T.F., et al. (2013). De novo truncating mutations in ASXL3 are associated with a novel clinical phenotype with similarities to Bohring-Opitz syndrome. *Genome Med* 5, 11.
7. Skjei, K.L., Martin, M.M., and Slavotinek, A.M. (2007). KBG syndrome: report of twins, neurological characteristics, and delineation of diagnostic criteria. *Am. J. Med. Genet. A.* 143, 292–300.
8. Sirmaci, A., Spiliopoulos, M., Brancati, F., Powell, E., Duman, D., Abrams, A., Bademci, G., Agolini, E., Guo, S., Konuk, B., et al. (2011). Mutations in ANKRD11 cause KBG syndrome, characterized by intellectual disability, skeletal malformations, and macrodontia. *Am. J. Hum. Genet.* 89, 289–294.
9. GajECKa, M., Mackay, K.L., and Shaffer, L.G. (2007). Monosomy 1p36 deletion syndrome. *Am. J. Med. Genet. C. Semin. Med. Genet.* 145C, 346–356.
10. Rosenfeld, J.A., Crolla, J.A., Tomkins, S., Bader, P., Morrow, B., Gorski, J., Troxell, R., Forster-Gibson, C., Cilliers, D., Hislop, R.G., et al. (2010). Refinement of causative genes in monosomy 1p36 through clinical and molecular cytogenetic characterization of small interstitial deletions. *Am. J. Med. Genet. A.* 152A, 1951–1959.
11. Kang, S.H., Scheffer, A., Ou, Z., Li, J., Scaglia, F., Belmont, J., Lalani, S.R., Roeder, E., Enciso, V., Braddock, S., et al. (2007). Identification of proximal 1p36 deletions using array-CGH: a possible new syndrome. *Clin. Genet.* 72, 329–338.
12. Tsurusaki, Y., Okamoto, N., Ohashi, H., Kosho, T., Imai, Y., Hibi-Ko, Y., Kaname, T., Naritomi, K., Kawame, H., Wakui, K., et al. (2012). Mutations affecting components of the SWI/SNF complex cause Coffin-Siris syndrome. *Nat. Genet.* 44, 376–378.


13. Long, M., VanKuren, N.W., Chen, S., and Vibranovski, M.D. (2013). New gene evolution: little did we know. *Annu. Rev. Genet.* *47*, 307–333.
14. Shabalina, S.A., Ogurtsov, A.Y., Spiridonov, A.N., Novichkov, P.S., Spiridonov, N.A., and Koonin, E.V. (2010). Distinct patterns of expression and evolution of intronless and intron-containing mammalian genes. *Mol. Biol. Evol.* *27*, 1745–1749.
15. Karlson, J.R., Mørk, E., Holtlund, J., Laland, S.G., and Lund, T. (1989). The amino acid sequence of the chromosomal protein HMG-Y, its relation to HMG-I and possible domains for the preferential binding of the proteins to stretches of A-T base pairs. *Biochem. Biophys. Res. Commun.* *158*, 646–651.
16. Eberl, H.C., Spruijt, C.G., Kelstrup, C.D., Vermeulen, M., and Mann, M. (2013). A map of general and specialized chromatin readers in mouse tissues generated by label-free interaction proteomics. *Mol. Cell* *49*, 368–378.
17. Lim, J., Hao, T., Shaw, C., Patel, A.J., Szabó, G., Rual, J.F., Fisk, C.J., Li, N., Smolyar, A., Hill, D.E., et al. (2006). A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. *Cell* *125*, 801–814.
18. Nozawa, R.S., Nagao, K., Masuda, H.T., Iwasaki, O., Hirota, T., Nozaki, N., Kimura, H., and Obuse, C. (2010). Human POGZ modulates dissociation of HP1alpha from mitotic chromosome arms through Aurora B activation. *Nat. Cell Biol.* *12*, 719–727.
19. Shalaby, M.A., Hampson, L., Oliver, A., and Hampson, I. (2011). Identification of PlexinD1 and AHDC1 as a putative interactors for Tip-1 protein. *Genes & Genomics* *33*, 399–405.
20. Wong, K.A., Wilson, J., Russo, A., Wang, L., Okur, M.N., Wang, X., Martin, N.P., Scappini, E., Carnegie, G.K., and O'Bryan, J.P. (2012). Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks. *PLoS ONE* *7*, e36023.
21. Vandamme, J., Völkel, P., Rosnoblet, C., Le Faou, P., and Angrand, P.O. (2011). Interaction proteomics analysis of polycomb proteins defines distinct PRC1 complexes in mammalian cells. *Mol. Cell. Proteomics* *10*, 002642.
22. Schoenberg, D.R., and Maquat, L.E. (2012). Regulation of cytoplasmic mRNA decay. *Nat. Rev. Genet.* *13*, 246–259.

The American Journal of Human Genetics, Volume 94

Supplemental Data

**De Novo Truncating Mutations in *AHDC1*
in Individuals with Syndromic Expressive
Language Delay, Hypotonia, and Sleep Apnea**

Fan Xia, Matthew N. Bainbridge, Tiong Yang Tan, Michael F. Wangler, Angela E. Scheuerle, Elaine H. Zackai, Margaret H. Harr, V. Reid Sutton, Roopa L. Nalam, Wenmiao Zhu, Margot Nash, Monique M. Ryan, Joy Yaplito-Lee, Jill V. Hunter, Matthew A. Deardorff, Samantha J. Penney, Arthur L. Beaudet, Sharon E. Plon, Eric A. Boerwinkle, James R. Lupski, Christine M. Eng, Donna M. Muzny, Yaping Yang, and Richard A. Gibbs



MRI Finding	Patient 1	Patient 2	Patient 3	Patient 4
Thin Corpus callosum	N.D.	+	+	+
Gyral simplification or under-operculization	+	+	+	N.D.
Cerebellar Folia simplification	N.D.	+	+	N.D.
Retrocerebellar cyst	+	-	+	-

N.D.= Not determined due to patient age (Patient 1) or image availability (Patient 4)

Figure S1: Brain MRI findings in patients with *de novo* *AHDC1* mutations (A) Patient 1 at 4 months- T2 demonstrates the presence of a retrocerebellar cyst. (B) Patient 3 at 3 months- T2 demonstrates thinning of the corpus callosum which can be seen in normal individuals at this age. (C) Patient 3 at 8 years- FLAIR sequence confirms thin corpus callosum, persisting at this age constituting an abnormal finding related to white-matter.(D) Patient 3 at 8 years- T2 demonstrates simplification of the cerebellar folia. (E) Patient 2 at 3 years- T1 demonstrates slumping of the posterior fossa and thinning

of the corpus callosum (F) Patient 2 at 3 years- T1 axial section demonstrates relative paucity of white matter at 3 years (G) Patient 2 at 3 years-T1 coronal sequence demonstrates thinning of the corpus callosum, gyral simplification and paucity of white matter (H) Patient 4 at 10 years- T1 sagittal section demonstrates thinning of the corpus callosum. (I) Tabulation of major MRI findings in the 4 patients, some features could not be determined due to patient age or image availability.




Figure S2: Expression patterns of *AHDC1*, *FOXG1* and *ARID1A* (From Genecards <http://genecards.org/>).

AHDC1_HUMAN 1 MRVKPQGLVVTSSAVCSSPDYLRPKYYPGGPPTPRPLLPTRPPASPPDKAFSTHAFSEN
Ahdcl_MOUSE 1 MRVKPQGLVVTSSAVCSSPDYLRPKYYPGGPPTPRPLLPTRPPASPPDKAFSTHTFSEN
Ahdcl_Danio_r 1 -----
Ahdcl_Xenopus_t 1 -----

AHDC1_HUMAN 61 PRPPRRDPSTRRPPVLAKGDDPLPPRAARPVSAQARCPTPVGDGSSSRRCWDNGRVNLRP
Ahdcl_MOUSE 61 PRPPRRDPSSRRPPVLAKGDDLLPPRAARPVSAHCPSAPADNS-SLRHWDNGRVNLRP
Ahdcl_Danio_r 1 -----
Ahdcl_Xenopus_t 1 -----NGRVNLQP

AHDC1_HUMAN 121 VVQLIDIMKDLTRLSQDLQHSGVHDCGGLRLS-----RPP-A
Ahdcl_MOUSE 120 VVQLIDIMKDLTRLSQDLQHSGVHDCGGLRLS-----RPP-A
Ahdcl_Danio_r 1 -----MSRLSGRLRSGGVRILTCEALPEKDCNDDEGPSLWEGDAEPEATSMGPSDA
Ahdcl_Xenopus_t 9 VVRLMDIMKDLSQLSSDLQSSGVRILDCTHVASS-----PSESE

AHDC1_HUMAN 158 PPPGDLQYSFFSSPSLANSIRSPEERATPHAKSERPSHPLYEPEPEPRDSPQPGQGHSPG
Ahdcl_MOUSE 157 PPPGDLQYSFFSSPSLANSIRSPEERANPHTKSERPSHPLYEPEPEPRDSPQPGQGHGPG
Ahdcl_Danio_r 51 NPASALHYNFYSPPSLANGLRNHEEQLRRRARRRRPTEYVEQIHTQEQR--IQONTQPO
Ahdcl_Xenopus_t 47 NAEPGLQYSFFSSQSLACGLRSPEEKPSSETVEKEPV-----

AHDC1_HUMAN 218 A---TAAATGLPPEPEPDSTDYSELADADILSELASLTCPEAQLLAQAL-EPP-----
Ahdcl_MOUSE 217 A---AATATGLPPEPEPDGPDYSELADADILSELASLTCPEAQLLAQAL-EPP-----
Ahdcl_Danio_r 109 MHSLTQPSTHLQ-----PHTHIPVDAHLWVDTNTLTHKHSQ---KGMCT-
Ahdcl_Xenopus_t 83 -----PVSPNPDS---MESASSEVLRRLAALAWMEPQOTESKGEIEEDQGESKQ

AHDC1_HUMAN 268 ---SPEP-----EPQLLDQPFRFLDPQALEPLGEALELPPLQPLADPLGLPGLALQAL
Ahdcl_MOUSE 267 ---SPQP-----EPQLLDQPFRFLDPQALEPLGEGLELPPLQPLADPLGLPSLTLQAL
Ahdcl_Danio_r 150 ---PT-----SASLMELDPSLIPEDLS-LPSKTEVHSVQVQPAPLLHT----TL
Ahdcl_Xenopus_t 129 DEESSEDEQDEGAGDNEAEDPTDGKMN-----EQGDIT---LVQ--ENQLNLKDMGVASL

AHDC1_HUMAN 318 DTL-----PDSLESQLLDPQALDPLPKLLDVPGRRLPEQQPLGHCP
Ahdcl_MOUSE 317 DTL-----PDSLESQLLDPQALDPLPKLLDVPGRRLPEQQSLGHCP
Ahdcl_Danio_r 191 D-----TNTLTPP-----QYNPSSLPKEEHNSCK
Ahdcl_Xenopus_t 179 DADLKEQSSDEESREDESKQEEKTVEREVLIMETQMEQLPWMLPLFSPS-----

AHDC1_HUMAN 359 LA---EPLRLDLCSPHGPPGPEGHPKYALRRTRDRPKILCRRRKAGRGRKADAGPEGRLL
Ahdcl_MOUSE 358 LA---EPLRLDLCSPHGPPGPEGHPKYALRRTRDRPKILCRRRKAGRGRKADSGPEGRLL
Ahdcl_Danio_r 215 PEMDDSTGLEHIKGOAAAMTSVEAERKYTLRSSGRPRFPCHLRKSSRLRRAPED---HMF
Ahdcl_Xenopus_t 228 -V---DNIRRISFSHRGRFGHR-----GRRGDRPGR-GRRRRPGRPRASES-----

AHDC1_HUMAN 415 PLPM-----PTGLVAALAEPPPPPPPPPA---LPGGPG-VSVPELKPESS
Ahdcl_MOUSE 414 PLPM-----PTGLAAALAEPPPLPPPPPT---LSGGPG---VPELEPESS
Ahdcl_Danio_r 272 KRELQKDEEEEEENIVWRTEISQIVEHLPEVCAAE-SSFEVLPPTD--TSVDITPNHSM
Ahdcl_Xenopus_t 269 -----LSRAYVMPPYHRTPEEPYR--LHEQSLHFTHSINNPPSM

AHDC1_HUMAN 457 -----QT---PVVSTRKGKCRGVRRMVVKMAKIPVSLGRRNKTTYKVSSLSLSSV---
Ahdcl_MOUSE 454 -----QT---PMVPTRKGKCRGVRRMVVKMAKIPVSLGRRNKTTYKVSSLSLSSV---
Ahdcl_Danio_r 329 ITSEAEGSVTQSVRGRKQGRYIGVKRIVVKVARI PVHMSRRQK-SYKISSLEPVSAAPRG

Ahdcl1_Xenopus_t 308 -----ETPKKEGPPKPKPKRKGVRKMVVRIAKIPMPVGRNKT SYKVSFSSTLSV----

AHDC1_HUMAN 505 -----EGKELGLRVSAEPTPLMKMKNNGRNVVVVFPFGEMPIILKRKRGRPPK
Ahdcl1_MOUSE 502 -----EGKELGLRVSEPTPLMKMKNNGRNVVVVFPFGEMPIILKRKRGRPPK
Ahdcl1_Danio_r 388 EGVTTGEGPEGGVGSSEPVSNVPREPTALLRMKNNGKSMVMVFPFGELPVIILKRRRGRPPK
Ahdcl1_Xenopus_t 358 -----EGGELIGGSGPGPTSLLMKMKNNGRNVVMVFPFGELPIILKRRRGRPPK

AHDC1_HUMAN 553 NLLLGPGKPK-----EPAVVAAEAATVAATMAMPEVKKRRRRKQKLASQPSYAAD
Ahdcl1_MOUSE 550 NLLLGPGKPK-----EPTVVAAEAATVTAATMAMPEVKKRRRRKQKLASQPSYAAD
Ahdcl1_Danio_r 448 QALPGQPD--MH-----ETR-----VGAANAAPKKIIRRRRTVKLPSQPSYVND
Ahdcl1_Xenopus_t 406 NLVLAARETPPMLPQPPPKEPAALPPPTSQPPTPLPEGEMVKKRRRRKQKLPSQPSYVAD

AHDC1_HUMAN 605 ANDSKAEYSDVLAKLAFLNRQSQCAGRCSPRCWTPSEPEVSVHQAPDTQSISHFLHRVQG
Ahdcl1_MOUSE 602 ANDSKAEYSDVLAKLAFLNRQSQCAGRCSPRCWTPSEPEVSVHQAPDTQSISQFLHRVQG
Ahdcl1_Danio_r 491 TNDVKVEYADVLSKLAFLNRQPPSTGRCSPPRCWTPTEPETFNIPPENPSLSTLLHRLTG
Ahdcl1_Xenopus_t 466 ANDSKSEYSDVLAKLAFLNRQSQTAGRNSPPRCWTPTLPEVSVHQAPDTHSISQFLHRVQG

AHDC1_HUMAN 665 FRRRGGKAGGFGGRGGG--HAAKSARCSFSDFFEGIGKKKKVVAVAAGVGGPGLTELGH
Ahdcl1_MOUSE 662 FRRRGGKTGGFGGRGGG--HAAKAARCSFSDFFEGIGKKKKVVAVAAPGLVGPGLTELGH
Ahdcl1_Danio_r 551 FRRRGGRAGCMGSRGGGAAGASSSFKRSFSDFFETIGKRRKVPASEP-----GT
Ahdcl1_Xenopus_t 526 YRRRGGRGGGPGRRGGCNSHNPELSRCSFSDFFEGIGKKKTKARPVD-----PLKP

AHDC1_HUMAN 723 PRKRGRGE-----VDAVTGPKPKRRSRKNGTLFPEQVPSGPGFGEAGA EWAGDK-
Ahdcl1_MOUSE 720 PRKRGRGE-----VDAVTGPKPKRRSRKNGTLFPEQVPSGPGFGEAGA EWVGDK-
Ahdcl1_Danio_r 600 PRKRKGGAAGGINRAALADSAQGEKVRKRRPRKNGALKNGPGVQEQDQONENSSWIGKGD
Ahdcl1_Xenopus_t 577 RKRROQRA-----EPDPNAKPKRKR SRKNGALLGEMGGEGSLGYQGTSEWGPEGK

AHDC1_HUMAN 773 GGGWAPHHGHGPGQAGRNCGFQGTEARAFAS TGL ESGASGRGSYYS TGA-PSGQTELSQE
Ahdcl1_MOUSE 770 GGGWAPHHGHGPGQAGRNCGFQGTEARAFAS TGL ESGASGRGSY Y A-GA-PSGQTELSQE
Ahdcl1_Danio_r 660 IPE-----KAGSYQSPCSPRGS----F-----QSSDGTKGGMYHSPG--MRGVGSGEE
Ahdcl1_Xenopus_t 628 GTPWPGQLS-HSQSGGRHCSYQGPENRGFSSM--HSGSPNRPSYYAGAGSVSHAEGGGQD

AHDC1_HUMAN 832 RQNLFTGYFRSLLDSDSDLLDFALSA--SRPESRKASGT YAGPPTSALPAQRGLATFP
Ahdcl1_MOUSE 828 RQNLFTGYFRSLLDSDSDLLDFALSA--SRPESRKASGT YAGPPSSALPAQRGLATFP
Ahdcl1_Danio_r 702 SQGLFAGYFRSLLDSDSDLLDISMSSPAGRQESRKLTPGYEGGSPGA--AHRWSPAFP
Ahdcl1_Xenopus_t 685 RHLFTGYFRSLLDSDSDLVDFAMAA--QRQEARKSASAFSGSSSS--PNTRALQSYS

AHDC1_HUMAN 890 SRGAKASP VAVGSSGAGADPSFQPVLSARQTFPPGRAASYGLTPAASDCRAAETFPKLV P
Ahdcl1_MOUSE 886 SRGAKASP VAVGSSGAGADPSFQPVLP SRQTFPPGRATSYGITPATSDCRAAETFPKLAP
Ahdcl1_Danio_r 760 KRSPKGAACIGDGAQLSSPQTQGSSTT-----KSSYSYSV--SQTSPTPSFPK--S
Ahdcl1_Xenopus_t 741 N-----SRGTKASAQESAYQSSAPARQOFPSPRGSSNYAALNQDCHGSDAFQKLV S

AHDC1_HUMAN 950 PPSAMARSPTTHPPANTYLPQYGGYGA-----GQSVFAPTKPF--TGQDCANSKDCSF
Ahdcl1_MOUSE 946 PPSAVARSPTTHPPANTYPPQYGGYGA-----GQSVFASAKPF--SGQDCANSKDCSF
Ahdcl1_Danio_r 807 PALLLSRSPSSPHPSGGFPQYPPNYSAG---VPQGG S---IYPLPQQQQQQQRPSDCSF
Ahdcl1_Xenopus_t 793 RS-----PNSHHT--GGFSQYSGFSGTGGQSLPSHGLFAPNKQYPSGPPDCAGNKDCSF

AHDC1_HUMAN	1001	AYGSGNSLPASPSSAHSAGYA-----PPPTGGPCLPPSKASFFSSEGAPFSGSAPTPL
Ahdc1_MOUSE	997	AYGSGNSLPASPSSAHSAGYA-----PPPTGGPCLPPSKASFFNSSEGGPFSGSAPTPL
Ahdc1_Danio_r	860	TYGTTKTP--SVPSAQCQMSYSNYQG-----SAKRNYSYYPGPPHST-----
Ahdc1_Xenopus_t	845	SFSGNSLPSSPGSAHSGTGFSHQQQQQLPAVGSQVNMNPKNPFNTSEVPPF-----PPL
AHDC1_HUMAN	1055	RCDSRAS TVSPGGYMPVKGT TASATS AASA A S S S S S S F Q P S P E N C R Q F A - G A S Q W P F R Q G
Ahdc1_MOUSE	1051	RCDSRAS TVSPGGYMPVKGT TASAA S --- V A S S S S S S F Q P S P E N C R Q F V - G A S Q W P F R Q G
Ahdc1_Danio_r	899	TQRGESGPTSPGGSYMSMSKSSPY-----SLSSSPPEGCRQYT---AQWGYRQG
Ahdc1_Xenopus_t	900	RSESRSGTSSPANYMLPKAAGSLF-----P-GENSRTFPGTSSQWAFRQG
AHDC1_HUMAN	1114	YGGLDWASEAFSQL-----YNPSFDCHVSEPNVILDISNYTPQKVKQQTAVSETFSESSS
Ahdc1_MOUSE	1107	YGGLDWASEAFSQL-----YNPNFDCHGSEPNVILDISNYTPQKVKQQTAVSETFSESSS
Ahdc1_Danio_r	945	--GNNWGGDAYGSHQFHGYSEYGVAGTGSESKDILDISNYTPQKAKQRPCI-DTLSESSS
Ahdc1_Xenopus_t	944	YSQTDWGPDSFGQL-----YGAGFDCHMTESNVILDISNYTPQKAKQNT---DNISESSS
AHDC1_HUMAN	1169	DSTQFNQPVGGGGFR---RANSEASSSEGGQSSLSLEKLMMDWNEASSAPGYNWNQSVLF
Ahdc1_MOUSE	1162	DSTQFSQPVGGGGFR---RANSEASSSEGGQSSLSLEKLMMDWNEASSAPGYNWNQSVLF
Ahdc1_Danio_r	1002	DS SHTGGGGGGASVVGAAFRPRDVPMEGQSSLSLEKLMIDWNENSAGPSYNWNSQNVLF
Ahdc1_Xenopus_t	996	DSTQYTQP--GAGYR---RANSEASSSEGGQSSLSLEKLMMDWNETSSAPGYSWNQSVLF
AHDC1_HUMAN	1226	QSSSKPGRGRRKKVDLFEASHLG-----FPTSASAAASGYPSKRSTGPRQPRGGRGGGAC
Ahdc1_MOUSE	1219	QSSSKPGRGRRKKVDLFEASHLG-----FSTSTSATASGYPSKRSTGPRQPRGGRGSGAC
Ahdc1_Danio_r	1062	QGGAKPGRGRRKKSEAHNEKESCSLPPGSPASP-PMQGAGPKRSSTGGRQPRGARARGGGF
Ahdc1_Xenopus_t	1051	HHTAKPGRGRRKKADIFEP SHPH-----H-----HHLTGFPSKRGGGPRGPRGGRGGGCS
AHDC1_HUMAN	1281	SAKK-ERGGAAAKAKFIPKQ-----PVNPLFQDSPDLGLDYSGDSSMSPLPSQSR
Ahdc1_MOUSE	1274	SAKK-ERGGTAAKAKFIPKQ-----PVNPLFQDSPDLGLDYSGDSSMSPLPSQSR
Ahdc1_Danio_r	1121	SPCQRDRPPPKTK---SQKPSAPSGSQMGSGAVY----QEALDYSGDSSLSPLS---
Ahdc1_Xenopus_t	1101	TNRK-ERGS--KAKFVPKPPAPPSS--SVSSLFQESSELGLDCYSGDSSMSPLPSHR
AHDC1_HUMAN	1332	AFGVGERD-PCDFIGPYSMNPSTPSD-GTFGQGFHCDSPSLGAPEL----DGKHFPLA-
Ahdc1_MOUSE	1325	AFGVGERD-PCDFMGPYSMNPSTPSD-GTFGQGFHCDSPSLGAEL----DGKHFPLA-
Ahdc1_Danio_r	1171	----HAPESCEYPSYSVHTSTPSSDERFAHVYPPDSASVSPSLSIQSDALKQFPKSGP
Ahdc1_Xenopus_t	1156	AYSVGERDPPCDFSGPYSMNPSTPSD-GTFGF--QSDSPGLCPPTTE-LEPGKHFSLPP
AHDC1_HUMAN	1385	-----HPPTV----FD-AGLQKAYSPTCSPTLGFKEE--LRPPPTKLAACEPLKHG
Ahdc1_MOUSE	1378	-----HPPTV----FD-AGLQKAYSPTCSPTLGFKEE--LRPPPSKLTACEPLKHG
Ahdc1_Danio_r	1226	T-----AQTYG--HAARTFSPNLSPTPRLLPQCGSAMSPhR-----
Ahdc1_Xenopus_t	1212	SGSATS GAPHPPPPGLGYEHMQDSPFSPNC SPTLELRPGEGRKLVPSSSHSSCDPLKHS
AHDC1_HUMAN	1429	LQGASLGHAAAQAHLSCRD----LPLGQPHYDSPCKGTAYWYPPGSAARSPPYEGKVG
Ahdc1_MOUSE	1422	LQGASLSHA--QAHLSCRD----LPLGQPHYDSPCKGTAYWYPPGSAARSPPYEGKVG
Ahdc1_Danio_r	1260	-----V--PKDQFSQYDSPSYSGSPCWYGGGQSVAGSPQNYEE-
Ahdc1_Xenopus_t	1272	LPPHL-----PSCREQLPSQPSTHHRYPSPCKNAGYWYPPR----SPPYDGKG-
AHDC1_HUMAN	1485	TGLLADFLGRTEA--ACLSAPHLASPPATPKADKEPLEMARPPGPPRGPAAAAAGYGCPL
Ahdc1_MOUSE	1476	SGLLADFLGRTEA--VCLSAPHLASPPATPKADKEPLEMARPPGPPRGPAATAAGYGCPL
Ahdc1_Danio_r	1296	-----QRT-----PAVSLP--SQKRDM--SLMVSGM-----RIASHTSYPSPL

```

Ahdc1_Xenopus_t 1317 -GLLSDFMGRRGEGASCL-SPHIP----SPKRDKETLDMMRG-----HHRAPYPCPL

AHDC1_HUMAN      1543 LSDLTLSPPV----RDSLLPLQDTAYRYPG----FMPQAHPLGG-GPKSGFLGPM AEPH
Ahdc1_MOUSE      1534 LSDLTLSPPV----RDSLLPLQDTAYRYPG----FMPQAHPLGG-GPKSGFLGPM AEPH
Ahdc1_Danio_r    1330 QRGPSMSTSCVSGTLDS SPQHE--EMGYHGNLESYAPVQ-QRYAPQTARGGVLCQLLDQP
Ahdc1_Xenopus_t 1363 LSDITHSPVQ----RDSMVQLQE-TYRYPA----FPPQGPPVLSPPNMKGGFLGPEN--I

AHDC1_HUMAN      1594 PEDTFTVTSL
Ahdc1_MOUSE      1585 PEDTFTVTSL
Ahdc1_Danio_r    1387 SDEGFTVTSL
Ahdc1_Xenopus_t 1412 PEDNFTVTSL

```

Figure S3: Sequence alignments of AHDC1 in select vertebrates.

SUBJECT	#1	#2	#3	#4
Sex	Female	Female	Male	Male
Age	18 mo	4 yo	8 yo	11 yo
Major Concern	Global developmental delay, hypotonia	Global developmental delay, hypotonia	Micrognathia, developmental delay	Autism, epilepsy, developmental delay, cortical visual impairment
Birth	Term	Term	Term	38w
Weight	<3%	25%	25%	20%
Height	10%	10%	50%	5%
HOC	50%	50%	60%	75%
Head/Face/Neck	Relative macrocephaly; anterior fontanelle not wide	Normal	Plagiocephaly, Mild synophrys	Relative macrocephaly
Ears	Low set tympanostomy tubes for middle ear effusions	Protuberant	Low set, protuberant, large helices with small/absent lobes	Left ear simple with upturned earlobe
Eyes	Intermittent esotropia, hyperopia, upslanting palpebral fissures, horizontal eyebrows, possible cortical visual impairment	Upslanting palpebral fissures	Hypertelorism, downslanting palpebral fissures. horizontal eyebrows, Mild ptosis.	Hypertelorism, esotropia, hyperopia, horizontal eyebrows,
Mouth	Tented vermilion of upper lip, micrognathia, high arched palate	No	Micrognathia requiring surgery. Small mouth. Limited jaw opening.	Tented vermilion of upper lip
Nose	Flat nasal bridge, anteverted nares	Flat nasal bridge	Normal	Flat nasal bridge, anteverted nares
Teeth	Normal eruption; teeth grinding	No	Normal	Wide spaced
Anatomic Upper Airway obstruction	Laryngomalacia	Obstructive sleep apnea	Laryngomalacia	Tracheomalacia, resolved
Gastrointestinal	Feeding problems	No	Chewing problem	G-tube fed, constipation
Genitalia	Normal external genitalia	Normal	Small penis	Normal
Hands and Feet	Clinodactyly, small hands and feet, positional talipes	Normal	Index fingers tapered with narrow nails.	Small hands and feet, persistent fetal finger

	equinovarus		Wide gap between Left index and middle fingers. Right transverse plamar crease.	pads(also on the toes), 2,3 toe syndactyly
Chest	Broad chest, wide-set nipples	Normal	Normal	Normal
Central Nervous System	Global developmental delay	Global developmental delay	Global developmental delay	Global developmental delay
Intellectual Disability	Not evaluated due to the young age	Moderate	Mild	Moderate
Hypotonia	Severe	Yes	Yes	Yes
Sit	With support	19 mo	9 mo	15 mo
Walk	Not crawling	2 yo	18 mo	27 mo with walker, can now scoot, walks 15-20 feet with walker, wheelchair for long distances
Speech	Delayed; only babbling at 18 months	Delayed (2-3 words)	Delayed (First words just after 1 yo. Persistent speech therapy.)	Delayed, Vocalizes, no words
Seizures	None	None	Multiple episodes	Focal epilepsy with gelastic seizures diagnosed at 8 years, progressive
Sleep Abnormalities	Obstructive sleep apnea requiring CPAP	Obstructive sleep apnea	Obstructive sleep apnea, occasional central apnea.	Wakes for long periods at night, sleepiness during day, no history of sleep apnea
Autistic/Behaviour	Some stereotypic hand movements	No. Good eye contact	No	Yes
MRI Imaging (see also Supplementary Figure One)	Subtle hyperintensities in midbrain, pons and globus pallidi on T2 and FLAIR imaging; retro-cerebellar cyst. Gyral simplification	Gyral simplification, hypoplasia of the corpus callosum	Hypoplasia of the corpus callosum, gyral simplification, and mega cisterna magna.	Hypoplasia of the corpus callosum
Misc.	Mild self-resolving hepatomegaly	Chronic ear infections	Echocardiogram normal.	Scoliosis, echocardiogram normal
Family History	Negative; one	Negative, first	Negative, one	Negative, two

	healthy sibling	child	healthy sibling	healthy siblings
Metabolic Work up	Negative	Negative	Acylcarnitine profile, carnitine levels and lactate normal	Negative
Prior Genetic Testing (negative)	Myotonic dystrophy, SMA, PWS, CMA	FX, MECP2, CMA, AOH on chromosome 5	CMA, FX, RASopathy gene panel	SMA, PWS, SMS, Fragile X, TCF4, MED12, ATRX, CMA
AHDC1 Mutations	c.2373_2374delTG, p.Cys791Trpfs*57	c.2898delC, p.Tyr967Thrfs*175	c.2373_2374delTG, p.Cys791Trpfs*57	c.2547delC, p.Ser850Profs*82

Table S1: Detailed clinical features of probands.